Revance Therapeutics appoints new CMO
This article was originally published in Scrip
Revance Therapeutics, a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, has named Arthur P Bertolino executive vice-president and chief medical officer. Dr Bertolino, a Board Certified dermatologist and dermatology industry executive, will join the company on 2 September 2014. Most recently he was vice-president of dermatology for Novartis Institutes for Biomedical Research (NIBR).